AbbVie Inc. (ABBV)
AbbVie Inc is an American multinational biopharmaceutical company based in North Chicago, Illinois. It was created in 2013 as a spin-off of Abbott Laboratories. AbbVie is focused on developing and marketing advanced therapies for severe and chronic conditions, emphasizing oncology, immunology, and virology.
Company Info
US00287Y1091
00287Y109
Jan 2, 2013
Highlights
$351.09B
$2.34
84.82
0.42
$57.37B
$44.44B
$16.33B
$148.19 - $216.66
$210.68
0.95%
1.80
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in AbbVie Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
AbbVie Inc. (ABBV) returned 6.39% year-to-date (YTD) and 19.87% over the past 12 months. Over the past 10 years, ABBV delivered an annualized return of 15.79%, outperforming the S&P 500 benchmark at 10.43%.
ABBV
6.39%
6.62%
-5.71%
19.87%
22.17%
15.79%
^GSPC (Benchmark)
-3.70%
13.67%
-5.18%
9.18%
14.14%
10.43%
Monthly Returns
The table below presents the monthly returns of ABBV, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 4.46% | 13.67% | 0.23% | -6.02% | -4.88% | 6.39% | |||||||
| 2024 | 7.10% | 7.09% | 3.44% | -9.85% | -0.86% | 6.38% | 9.04% | 5.93% | 0.60% | 4.07% | -10.27% | -2.86% | 18.87% |
| 2023 | -7.71% | 4.16% | 3.55% | -4.30% | -8.71% | -2.34% | 12.25% | -1.75% | 1.43% | -4.34% | 0.86% | 8.83% | -0.23% |
| 2022 | 2.15% | 7.95% | 9.70% | -8.62% | 0.33% | 3.93% | -5.42% | -6.31% | -0.19% | 10.19% | 10.10% | 0.27% | 24.01% |
| 2021 | -3.24% | 5.13% | 0.45% | 4.28% | 1.52% | -0.49% | 4.40% | 3.85% | -10.69% | 7.59% | 0.53% | 17.45% | 32.43% |
| 2020 | -7.26% | 5.79% | -11.11% | 9.50% | 12.74% | 5.95% | -2.15% | 0.91% | -8.54% | -1.52% | 22.89% | 2.46% | 27.72% |
| 2019 | -11.84% | -1.31% | 1.70% | -0.18% | -3.38% | -5.20% | -6.99% | -1.32% | 15.18% | 6.59% | 10.28% | 0.92% | 1.47% |
| 2018 | 16.87% | 3.22% | -18.29% | 3.06% | 2.48% | -6.36% | 0.56% | 4.07% | -1.46% | -16.81% | 21.09% | -2.21% | -0.96% |
| 2017 | -1.43% | 1.19% | 5.37% | 2.20% | 0.12% | 9.83% | -2.72% | 7.71% | 18.01% | 2.27% | 7.39% | -0.22% | 60.07% |
| 2016 | -6.35% | -0.53% | 4.60% | 7.82% | 3.16% | -1.62% | 7.92% | -3.22% | -1.61% | -10.74% | 9.00% | 2.99% | 9.79% |
| 2015 | -7.09% | 0.25% | -3.24% | 11.37% | 2.98% | 0.90% | 4.97% | -10.86% | -12.82% | 10.46% | -2.35% | 1.87% | -6.50% |
| 2014 | -6.04% | 3.41% | 0.96% | 2.23% | 4.32% | 3.88% | -6.56% | 5.62% | 4.49% | 10.69% | 9.05% | -5.43% | 27.92% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of ABBV is 74, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for AbbVie Inc. (ABBV) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
AbbVie Inc. provided a 3.44% dividend yield over the last twelve months, with an annual payout of $6.38 per share. The company has been increasing its dividends for 11 consecutive years.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $6.38 | $6.20 | $5.92 | $5.64 | $5.20 | $4.72 | $4.28 | $3.59 | $2.56 | $2.28 | $2.02 | $1.66 |
Dividend yield | 3.44% | 3.49% | 3.82% | 3.49% | 3.84% | 4.41% | 4.83% | 3.89% | 2.65% | 3.64% | 3.41% | 2.54% |
Monthly Dividends
The table displays the monthly dividend distributions for AbbVie Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $1.64 | $0.00 | $0.00 | $1.64 | $0.00 | $3.28 | |||||||
| 2024 | $1.55 | $0.00 | $0.00 | $1.55 | $0.00 | $0.00 | $1.55 | $0.00 | $0.00 | $1.55 | $0.00 | $0.00 | $6.20 |
| 2023 | $1.48 | $0.00 | $0.00 | $1.48 | $0.00 | $0.00 | $1.48 | $0.00 | $0.00 | $1.48 | $0.00 | $0.00 | $5.92 |
| 2022 | $1.41 | $0.00 | $0.00 | $1.41 | $0.00 | $0.00 | $1.41 | $0.00 | $0.00 | $1.41 | $0.00 | $0.00 | $5.64 |
| 2021 | $1.30 | $0.00 | $0.00 | $1.30 | $0.00 | $0.00 | $1.30 | $0.00 | $0.00 | $1.30 | $0.00 | $0.00 | $5.20 |
| 2020 | $1.18 | $0.00 | $0.00 | $1.18 | $0.00 | $0.00 | $1.18 | $0.00 | $0.00 | $1.18 | $0.00 | $0.00 | $4.72 |
| 2019 | $1.07 | $0.00 | $0.00 | $1.07 | $0.00 | $0.00 | $1.07 | $0.00 | $0.00 | $1.07 | $0.00 | $0.00 | $4.28 |
| 2018 | $0.71 | $0.00 | $0.00 | $0.96 | $0.00 | $0.00 | $0.96 | $0.00 | $0.00 | $0.96 | $0.00 | $0.00 | $3.59 |
| 2017 | $0.64 | $0.00 | $0.00 | $0.64 | $0.00 | $0.00 | $0.64 | $0.00 | $0.00 | $0.64 | $0.00 | $0.00 | $2.56 |
| 2016 | $0.57 | $0.00 | $0.00 | $0.57 | $0.00 | $0.00 | $0.57 | $0.00 | $0.00 | $0.57 | $0.00 | $0.00 | $2.28 |
| 2015 | $0.49 | $0.00 | $0.00 | $0.51 | $0.00 | $0.00 | $0.51 | $0.00 | $0.00 | $0.51 | $0.00 | $0.00 | $2.02 |
| 2014 | $0.40 | $0.00 | $0.00 | $0.42 | $0.00 | $0.00 | $0.42 | $0.00 | $0.00 | $0.42 | $0.00 | $0.00 | $1.66 |
Dividend Yield & Payout
Dividend Yield
AbbVie Inc. has a dividend yield of 3.44%, which is quite average when compared to the overall market.
Payout Ratio
AbbVie Inc. has a payout ratio of 62.12%, which is quite average when compared to the overall market. This suggests that AbbVie Inc. strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the AbbVie Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the AbbVie Inc. was 45.09%, occurring on Aug 15, 2019. Recovery took 330 trading sessions.
The current AbbVie Inc. drawdown is 13.55%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -45.09% | Jan 29, 2018 | 390 | Aug 15, 2019 | 330 | Dec 4, 2020 | 720 |
| -31.61% | Jul 29, 2015 | 61 | Oct 22, 2015 | 383 | May 2, 2017 | 444 |
| -21.92% | Apr 11, 2022 | 120 | Sep 30, 2022 | 320 | Jan 10, 2024 | 440 |
| -20.74% | Mar 11, 2025 | 29 | Apr 21, 2025 | — | — | — |
| -19.82% | Dec 8, 2014 | 43 | Feb 9, 2015 | 90 | Jun 18, 2015 | 133 |
Volatility
Volatility Chart
The current AbbVie Inc. volatility is 10.10%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
The chart below illustrates the trends in the financial health of AbbVie Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of AbbVie Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 2.6% positive surprise.
Valuation
The Valuation section provides an overview of how AbbVie Inc. is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for ABBV, comparing it with other companies in the Drug Manufacturers - General industry. Currently, ABBV has a P/E ratio of 84.8. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for ABBV compared to other companies in the Drug Manufacturers - General industry. ABBV currently has a PEG ratio of 0.4. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ABBV relative to other companies in the Drug Manufacturers - General industry. Currently, ABBV has a P/S ratio of 6.0. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ABBV in comparison with other companies in the Drug Manufacturers - General industry. Currently, ABBV has a P/B value of 105.6. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |